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Abstract
Background: The average population age is increasing and the incidence of age-related vascular complications is rising
in parallel. Impaired wound healing and disordered ischemia-mediated angiogenesis are key contributors to age-impaired
vascular complications that can lead to amputation. High-density lipoproteins (HDL) have vasculo-protective properties
and augment ischemia-driven angiogenesis in young animals. We aimed to determine the effect of reconstituted HDL
(rHDL) on aged mice in a murine wound healing model and the hindlimb ischemia (HLI) model.
Methods: Murine wound healing model—24-month-old aged mice received topical application of rHDL (50 μg/wound/
day) or PBS (vehicle control) for 10 days following wounding. Murine HLI model—Femoral artery ligation was performed
on 24-month-old mice. Mice received rHDL (40 mg/kg) or PBS, intravenously, on alternate days, 1 week pre-surgery and
up to 21 days post ligation. For both models, blood flow perfusion was determined using laser Doppler perfusion
imaging. Mice were sacrificed at 10 (wound healing) or 21 (HLI) days post-surgery and tissues were collected for
histological and gene analyses.
Results: Daily topical application of rHDL increased the rate of wound closure by Day 7 post-wounding (25 %, p < 0.05).
Wound blood perfusion, a marker of angiogenesis, was elevated in rHDL treated wounds (Days 4–10 by 22–25 %, p < 0.
05). In addition, rHDL increased wound capillary density by 52.6 %. In the HLI model, rHDL infusions augmented blood
flow recovery in ischemic limbs (Day 18 by 50 % and Day 21 by 88 %, p < 0.05) and prevented tissue necrosis and toe
loss. Assessment of capillary density in ischemic hindlimb sections found a 90 % increase in rHDL infused animals. In vitro
studies in fibroblasts isolated from aged mice found that incubation with rHDL was able to significantly increase the key
pro-angiogenic mediator vascular endothelial growth factor (VEGF) protein (25 %, p < 0.05).
Conclusion: rHDL can promote wound healing and wound angiogenesis, and blood flow recovery in response to
ischemia in aged mice. Mechanistically, this is likely to be via an increase in VEGF. This highlights a potential role for HDL
in the therapeutic modulation of age-impaired vascular complications.
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Background
Angiogenesis is an essential element in the regenerative
response to tissue damage. It occurs in healing wounds
and in response to ischemic injury. However, in
advanced age, this process becomes impaired and is
characterized by endothelial cell decline, altered inflam-
matory response and impaired neovascularization [1–3].
Consequently, impaired wound healing and disordered
ischemia-mediated angiogenesis become defining fea-
tures of age-impaired vascular complications. Aged indi-
viduals have higher mortality and increased rates of limb
amputation as a result of acute limb ischemia [4]. In
these circumstances, aged patients and animal models
are reported to exhibit reduced tissue production of
vascular endothelial growth factor (VEGF) and de-
creased hypoxia inducible factor (HIF)-1α stability and
activation [5, 6]. Whilst this provides functional and
mechanistic evidence for age-impaired wound healing
and ischemia-mediated angiogenesis, the key triggers for
these events have not been entirely elucidated. Recent
data also indicate that processes fundamental to aging
also play pivotal roles in cardiovascular disease associ-
ated with advanced age [7].
We have recently shown that high-density lipoproteins
(HDL) augment ischemia driven angiogenesis in vivo
and in vitro [8]. These effects in vitro were mediated via
a stabilization of HIF-1α [9] and an elevation in VEGF
[8]. We have also recently identified that reconstituted
HDL (rHDL) rescues diabetes-impaired neovasculariza-
tion [10]. Given the distinct mechanistic similarities
between the impairment of angiogenesis in diabetes and
in aging, we now seek to determine if rHDL can also
improve age-impaired angiogenesis. We investigated this
using two surgical murine models of wound healing and
hindlimb ischemia and find that rHDL augments wound
closure and hindlimb angiogenesis in aged mice. Clinical
trials that have raised HDL in patients with advanced
atheroma have been disappointing showing no benefit
on advanced plaque size, which may be related to the
age-induced failure of HDL function in the context of
advanced atherosclerosis and aging. Our studies high-
light an alternate therapeutic use of HDL for
angiogenesis-related diseases that is effective in the con-
text of aging, which may facilitate its eventual successful
translation in clinic.
Methods
Preparation of discoidal reconstituted HDL
Apolipoprotein A-I (apoA-I) was isolated from plasma
obtained from healthy humans by ultracentrifugation
and anion-exchange chromatography, as described pre-
viously [11]. The collection of human blood complied
with the ethical rules for human experimentation as
stated in the 1975 Declaration of Helsinki. Ethics were
obtained from the Sydney Local Health District Ethics
Review Committee. Discoidal reconstituted HDL (rHDL)
was prepared by cholate dialysis, complexing 1-
palmitoyl-2-linoleoyl-phosphatidylcholine (PLPC) and
apoA-I at an initial PLPC:apoA-I molar ratio of 100:1
(final PLPC:apoA-I molar ratio of 80:1). Protein concen-
tration of rHDL was determined using bicinchoninic
acid (BCA) assay (Thermo Scientific).
Murine wound healing model
All experimental procedures and protocols were con-
ducted with the approval from the Sydney Local Health
District Animal Welfare Committee, and conformed to
the Guide for the Care and Use of Laboratory Animals
(United States National Institute of Health). Aged male
24-month-old C57Bl/6 J mice were used for both stud-
ies. The wound healing surgery was conducted as previ-
ously described [12]. Two full-thickness excisions that
include the panniculus carnosus were created on the
dorsum, one on each side of the midline of the mouse.
A 0.5 mm thick silicone splint (Life Technologies, CA,
USA) was then placed around the wound with adhesive
and interrupted sutures. For each mouse, one wound
received rHDL (50 μg/wound/day) and the other PBS
(vehicle control), topically applied daily. A translucent
occlusive dressing (Opsite™ Flexfix™, Smith & Nephew,
London, UK) was then applied. Digital images were
taken and micro-callipers were used to measure the
wound area daily. Blood perfusion in the wound areas
was determined using laser Doppler perfusion imaging
(moorLDI2-IR, Moor Instruments, Devon, UK). Ten
days after wounding, both wounds were excised for
histological and gene analyses.
Hindlimb ischemia model
The hindlimb ischemia model was conducted as de-
scribed previously [8]. The left femoral artery and vein
were ligated (7-0 silk) above both the epigastrica and
profunda femoris before severing them distal to the
ligation. The femoral artery and vein were also
completely excised as distal as the popliteal from the
hindlimb of mice. A sham procedure was performed on
the opposite hindlimb. Mice received i.v. injections of
PBS (vehicle control) or rHDL (40 mg/kg) every second
day following surgery. Hindlimb blood reperfusion was
determined by laser Doppler perfusion imaging
(moorLDI2-IR, Moor Instruments) and performed prior
to and immediately following surgery, then at Days 2, 4,
7, 10, 13, 16, 18 and 21 post-surgery. Following sacrifice,
the gastrocnemius muscles of both ischemic and non-
ischemic limbs were collected for histological and gene
expression analyses.
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Immunohistochemistry
Wound tissues were fixed in paraformaldehyde (4 %)
and embedded in paraffin. Wound sections (5 μm) were
taken from the mid-point and assessed for the presence
of Mac-3+ macrophages (1:100, Santa Cruz) and CD31+
neovessels (1:100, Abcam) [10]. Gastrocnemius muscle
sections were frozen in OCT and fixed in 100 % metha-
nol. Hindlimb sections (5 μm) were assessed for the
presence of CD31+ neovessels (1:1000, Abcam), α-
smooth muscle actin+ arterioles (1:500, Sigma Aldrich)
and laminin (1:300, Merck Millipore) [10]. All images
were analyzed using Image-Pro Plus 4.5 software (Diag-
nostic Instruments, USA). The percentage of positive
staining was calculated for each high power field (mini-
mum of 3 fields per section) and the mean staining area
for each section calculated.
Histochemistry
To determine collagen deposition, paraffin embedded
wound sections were stained with Milligan’s trichrome
stain. All images were analyzed using Image-Pro Plus 4.5
software (Diagnostic Instruments, USA). The percentage
of positive staining was calculated for each high power
field (minimum of 3 fields per section) and the mean
staining area for each section calculated.
qRT-PCR
Total RNA was isolated from wounds and hindlimbs
with TRI reagent (Sigma Aldrich). The amount of RNA
was quantitated spectrophotometrically using a Nano-
DropTM (Thermo Scientific). 200 ng total RNA was re-
verse transcribed using the iScript cDNA synthesis kit
(Bio-Rad) in triplicate. All amplicons were amplified
using iQ SYBR Green Supermix (Bio-Rad) in a Bio-Rad
Cfx384 thermocycler and 20 pmol each of forward and
reverse primer for murine VEGF (F: 5’-GGCTGCTGT
AACGATGAAG-3’; R: 5’-CTCTCTATGTGCTGGCTT
TG-3’), HIF-1α (F: 5’-TCCCTTGCTCTTTGTGGTTG
GGT-3’; R: 5’-AACGTAAGCGCTGACCCAGG-3’), Siah1
(F: 5’-GACTGCTACAGCATTACCCACT-3’; R: 5’-GTTG
GATGCAGTTGTGCCG-3’), Siah2 (F: 5’-CTAACGCCC
AGCATCAGGAA-3’; R: 5’-GAACAGCCCGTGGTAGCA
TA-3’), PHD2 (F: 5’-ATCACCTGGATCGAGGGCAA- 3’;
R: 5’-CGTTCGGCCGTTTATCCTGT-3’), PHD3 (F: 5’-G
AGCCGGCTGGGCAAATACT-3’; R: 5’-GGGGTTGTCC
ACATGGCGAA -3’) and β2-microglobulin (B2M) mea-
sured as a reference gene (F: 5’-CAACGGCAGCATTTAT
AACCC-3’; R: 5’-CCCATTGATGATGGAGTGTGG-3’).
Relative changes in mRNA levels of the genes of interest
were normalized using the ΔΔCT method to murine B2M.
ELISA
Wound and hindlimb tissue samples were homogenized
with lysis buffer (80 mM Tris HCl, 10 mM NaCl, 50 mM
NaF, 5 mM Na4P2O7, 15 nM Triton-X). Protein levels of
mouse VEGF were determined from wound and hindlimb
lysates using commercially available human VEGF ELISA
kit (R&D Systems Inc).
Plasma lipid concentration
Total cholesterol concentrations were determined enzymat-
ically on mouse plasma using commercially available kits
(Roche Diagnostics). HDL cholesterol concentrations were
determined by enzymatic assay following precipitation of
apolipoprotein B containing lipoproteins with polyethylene
glycol. LDL levels were determined by subtracting total
HDL from total cholesterol [8]. Triglyceride levels were
determined enzymatically on mouse plasma using commer-
cially available kits (Roche Diagnostics).
In vitro studies
Fibroblasts isolated from aged mice (24 months) were
grown to 80 % confluency in DMEM media in hypoxia
(1 % O2/5 % CO2) and then incubated with either PBS
(control) or rHDL (600 μg/ml) for 16 h [8]. Treated cells
were lysed with radioimmunoprecipitation assay (RIPA)
lysis buffer (20 mM Tris-HCl, 1 mM EDTA, 1 mM
EGTA, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfo-
nyl fluoride, 1.5 μg/mL aprotinin, 1 μg/mL leupeptin,
1 μg/mL pepstatin, 1 mM sodium orthovanadate, and
0.2 % Triton X-100; pH 7.4). The protein concentration
was determined using the BCA Protein Assay (Thermo
Scientific, Waltham, MA, USA). Nitrocellulose mem-
branes were incubated in a primary antibody against
VEGF (1:1000, ab46154, Abcam, Cambridge, UK). Even
protein loading was confirmed with α-tubulin (1:1000,
ab40742, Abcam). Three donors were tested, each in
quintuplicate (n = 15 total).
Statistical analysis
Data are expressed as mean ± SEM. Differences between
treatment groups were calculated using unpaired two tailed
t-test or one-way ANOVA with Bonferroni’s comparison
test post hoc. Significance was set at a two-sided p < 0.05.
Results
Topical rHDL promotes wound closure and wound
angiogenesis in aged mice
We investigated the effect of topically applied rHDL in a
murine model that mimics human wound repair in aged
mice. Topical treatment of wounds with rHDL (50 μg/
wound/day), in 24-month-old mice, showed significantly
faster wound closure at Day 7 (25.6 %, p < 0.01) and Day
8 (22.2 %, p < 0.05) compared to PBS treated wounds
(Fig. 1a). Consistent with this, blood perfusion deter-
mined by laser Doppler imaging, as a marker of wound
angiogenesis, was significantly elevated in rHDL treated
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wounds from Days 4–10 (22–25 %, P < 0.05), compared
to PBS control (Fig. 1b).
The effect of rHDL on wound neovascularization, wound
macrophage content and collagen deposition
Wound sections were stained for CD31, a marker of
neovessels. Despite a 52.6 % increase in CD31+ stained
neovessels in rHDL treated wounds, there was no sig-
nificant difference in the number of neovessels between
wounds administered PBS or rHDL (Fig. 2a). Assessment
of macrophage infiltration in wound sections with Mac-
3 showed a non-significant increase in rHDL treated
wounds (Fig. 2b). Finally, we found that there was no
difference in collagen deposition between rHDL and
PBS treated wounds (Fig. 2c).
rHDL had no effect on gene expression of angiogenic
markers in wounds
To elucidate the mechanism for the effects of rHDL on
wound angiogenesis in aged mice, we examined the effect
of rHDL on the key angiogenic growth factor vascular
endothelial growth factor (VEGF). We found that topical
application of rHDL had no impact on wound VEGF
mRNA levels compared to PBS control wounds (Fig. 3a).
Furthermore, treatment with rHDL did not affect VEGF
protein levels in wounds (Fig. 3b). Hypoxia inducible factor
(HIF)-1α, a key transcription factor that promotes VEGF
expression in hypoxia, was not changed in wounds after
topical rHDL treatment at Day 10 post-wounding (Fig. 3c).
Examination of the post-translational modulators of HIF-
1α found that there were no differences in the ubiquitin
ligases Siah1 and Siah2 mRNA levels between rHDL and
PBS treated wounds (Fig. 3d – e). Similarly, both proyl hy-
droxylases PHD2 and PHD3 showed no difference between
rHDL and the PBS control group (Fig. 3f – g).
rHDL promotes ischemia-induced blood perfusion in aged
mice
Laser Doppler perfusion imaging showed that blood flow
was equally impaired across both treatment groups
following ligation (Fig. 4). However, systemic rHDL infu-
sions augmented blood flow in the ischemic hindlimbs
at all time points, reaching significance at Day 18 (50 %,
p < 0.05) and Day 21 (88 %, p < 0.05), compared to PBS
infused control mice (Fig. 4).
rHDL prevents tissue necrosis in ischemic hindlimbs of
aged mice
In support of our observations of improved blood flow
in rHDL infused aged mice, we observed that in ische-
mic hindlimbs there was no loss of toes in mice that had
been infused with rHDL (Fig. 5). In contrast, in the
hindlimbs of control mice that had been infused with
PBS, the loss of toes occurred in >60 % of mice. The loss
of toes occurred in the third week post-ligation and is
consistent with the failure of the control mice to mount
a substantial blood flow recovery response. The ability of
rHDL to prevent tissue necrosis is likely to be due to the
promotion of blood flow perfusion in the final week in
these mice.
The effect of rHDL on hindlimb neovascularization
Next, we sought to determine the effect of rHDL on
neovascularization by assessing capillary and arteriole
a b
Fig. 1 Topical rHDL promotes wound closure and wound angiogenesis in aged mice. Two full thickness wounds were created on the back flanks of
24-month-old C57Bl/6 J mice (n= 9/group). Mice received daily topical applications of rHDL (50 μg/wound) or PBS (vehicle). a Wound area was calculated
from the average of three daily diameter measurements of the x, y and z-axes. Wound closure is expressed as a percentage of initial wound area at Day 0;
b Blood flow perfusion was determined by laser Doppler imaging. Upper panels are representative Doppler images that depict high (red) to low (blue)
wound blood flow taken at Days 2 and 10. Blood perfusion was determined based on rHDL:PBS wound ratio, with values above 100 % indicating increased
blood perfusion with rHDL treatment relative to PBS control. Data is represented as mean ± SEM. Statistical analysis was performed by unpaired two-tailed
t-test. *p< 0.05, **p< 0.01 vs. PBS treated wounds
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density in ischemic and non-ischemic hindlimbs. Despite
>90 % increases in CD31+ neovessels in both the ische-
mic and non-ischemic hindlimbs of rHDL infused mice,
this did not reach significance when compared to
control PBS infused mice (Fig. 6a). Assessment of α-
actin+ arterioles revealed that there were very few arteri-
oles and that rHDL infusions did not change arteriole
number, in either ischemic or non-ischemic hindlimbs,
compared to PBS control (Fig. 6b).
The effect of rHDL on angiogenic markers in ischemic
hindlimbs
Examination of the post-translational HIF-1α modula-
tors Siah1 and Siah2 (Fig. 7a – b) and PHD2 and PHD3
(Fig. 7c – d) showed no significant effects on mRNA
levels in both ischemic and non-ischemic hindlimbs.
rHDL treated mice showed a non-significant trend
toward increased HIF-1α expression in ischemic hin-
dlimbs (Fig. 7e). VEGF mRNA levels were unexpectedly
lower in the ischemic hindlimbs of rHDL infused mice
compared to PBS control, 21 days post-ligation (p < 0.05;
Fig. 7f ). Furthermore, when hindlimb VEGF protein
levels were determined, no difference was found across
both groups (Fig. 7g).
rHDL increases VEGF in vitro in cells from aged mice
Incubation with rHDL caused a significant increase
(25 %, p < 0.0 %) in the key pro-angiogenic factor VEGF
in fibroblasts isolated from aged mice (Fig. 8).
rHDL infusions increase plasma total cholesterol and HDL
cholesterol
Systemic rHDL infusions elevated both total cholesterol
(p < 0.01; Fig. 9a) and HDL cholesterol (p < 0.01; Fig. 9b),
compared to PBS infused control mice. rHDL did not
affect plasma LDL or triglyceride levels (Fig. 9c – d).
This increase in HDL indicates that the tail vein injec-
tions were delivered successfully.
Discussion
Wound healing is a complex dynamic process and in
healthy humans consists of four distinct, but overlap-
ping, phases including: inflammation, granulation, re-ep-
ithelialization and tissue remodelling [13]. In advanced
age, however, this process becomes disrupted, and is in-
stead characterized by an altered inflammatory response,
delayed re-epithelialization and impaired angiogenesis
[14]. Impaired angiogenesis is also associated with age
[15] and numerous studies utilizing subcutaneous
a
b
c
Fig. 2 The effect of rHDL on wound neovascularization, wound macrophage content and collagen deposition. Two full thickness wounds were
created on the back flanks of 24-month-old C57Bl/6 J mice (n = 9/group). Mice received daily topical applications of rHDL (50 μg/wound) or PBS
(vehicle). On Day 10 post-wounding, wound tissue was collected and sectioned for: a Capillaries using immunohistochemistry for CD31+ (brown,
denoted by arrows); b Macrophage infiltration was identified in wound sections using immunohistochemistry for Mac-3+ (brown, denoted by
arrows); c Collagen deposition was determined using Milligan’s trichrome stain (blue). Photomicrographs represent wounds stained for CD31+,
Mac-3+ and collagen of PBS and rHDL wounds following sacrifice. Data is represented as mean ± SEM
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implant and excisional models have shown delayed
wound neovascularization in aged animals [16, 17]. The
current study found that topical application of rHDL im-
proved wound repair and wound angiogenesis in aged
mice. Furthermore, systemic delivery of rHDL aug-
mented blood flow recovery and prevented tissue necro-
sis in response to ischemia. Mechanistically these
changes may be mediated through an increase in VEGF.
These studies show the efficacy of HDL in the rescue of
aged-impaired wound repair and angiogenesis.
The potent vasculo-protective properties of HDL are
well known [18] and previous studies from our lab have
shown that in young mice rHDL augment wound clos-
ure and ischemia-driven angiogenesis [8, 19]. This is the
first study to show that rHDL can still effectively im-
prove wound closure and angiogenesis in aged mice in
a b
c
d e
f g
Fig. 3 rHDL had no effect on gene expression of angiogenesis markers in wounds. Two full thickness wounds were created on the back flanks of
24-month-old C57Bl/6 J mice (n= 9/group). Mice received daily topical applications of rHDL (50 μg/wound) or PBS (vehicle). On Day 10 post-wounding,
wound tissue was collected and RNA was isolated for qRT-PCR to assess gene expression or wound tissue was homogenized and used in ELISAs to assess
protein. Measured markers include: a VEGF mRNA; b VEGF protein; c HIF-1αmRNA; d Siah1 mRNA; e Siah2 mRNA; f PHD2 mRNA; and g PHD3 mRNA. Data
is represented as mean ± SEM
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which there are impairments in normal healing re-
sponses. Recent (and current) clinical trials that have
raised HDL have all been aimed at reducing advanced
atherosclerotic plaques in elderly individuals [20–23].
These studies have been disappointing, as they have
shown no cardiovascular benefit despite increases in
HDL of 11–70 %. This puts into question HDL raising
as a therapy to reduce advanced plaque. A number of
mechanisms may contribute to this failure including the
reduced ability of HDL to efflux cholesterol from ad-
vanced necrotic plaques in aged individuals [24]. Fur-
thermore, studies have found that the anti-atherogenic
and anti-oxidant properties of HDL become compro-
mised with aging and in patients with advanced coronary
artery disease (CAD). HDL isolated from elderly individ-
uals induces less macrophage cholesterol efflux and is
less able to inhibit LDL oxidation when compared to
HDL from young individuals [24]. HDL isolated from
elderly individuals is more susceptible to oxidation than
HDL isolated from young individuals [25], which has
been attributed to age-related decreases in PON1 [26].
HDL from CAD patients fails to activate eNOS or NO.
This has also been attributed to reductions in HDL-
associated PON1 [26]. Finally, oxidatively modified apoA-I
has impaired cholesterol efflux, is pro-inflammatory and is
abundant in established plaques [27, 28]. Collectively, these
studies suggest HDL functionality is compromised when
raised in an aged/diseased milieu in the context of CAD
and perhaps dietary antioxidant intake could counteract
this, although the data are still conflicting as to their effect-
iveness [29]. Our studies, however, clearly show that if tar-
geted to the right pathology such as wound repair and
impaired ischemia-mediated angiogenesis, rHDL can still
be strikingly effective in the context of aging. These findings
may be important for the targeting of the HDL raising in-
terventions in future clinical studies.
To further examine the impact of topical rHDL treat-
ment, wounds were assessed for markers of angiogenesis
and wound repair. The initial inflammatory phase of
wound healing is distinguished by the infiltration of macro-
phages, which release pro-inflammatory growth factors
such as VEGF, to promote vascular permeability and
Fig. 4 rHDL promotes ischemia-induced blood perfusion in aged mice. Femoral artery ligation was performed on 24-month-old C57B1/6 J mice
(n = 6–8) to induce ischemia in hindlimbs. Mice received intravenous injections of PBS or rHDL (40 mg/kg) on alternate days following ligation
until sacrifice 21 days later. Images represent high (red) or low (blue) blood flow in animals treated with PBS or rHDL at Day 21. Laser Doppler
Perfusion Index (LDPI) was determined as a ratio of ischemic (ISC) to non-ischemic (NON ISC) hindlimbs. Data is represented as mean ± SEM.
Statistical analysis was performed by unpaired two-tailed t-test. *p < 0.05 vs. PBS control
PBS rHDL 
ISC NON-ISC ISC NON-ISC 
Fig. 5 rHDL prevents tissue necrosis in ischemic hindlimbs of aged mice. Femoral artery ligation was performed on 24-month-old C57B1/6 J mice
(n = 6–8) to induce ischemia in hindlimbs. Mice received intravenous injections of PBS or rHDL (40 mg/kg) on alternate days following ligation
until sacrifice 21 days later. Images are representative mouse feet at Day 21
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fibroblast activity. Age related alterations in wound repair
are marked by delayed macrophage infiltration in young
and middle-aged mice [30]. The next phase of wound heal-
ing is characterized by angiogenesis (capillary growth),
granulation and ultimately collagen synthesis [31]. We
found that there were non-significant increases in wound
capillaries and macrophages. The lack of significant effect
is likely because the increase in the inflammatory response
and requirement for angiogenesis post-wounding occurs in
the early stages of wound repair. Our histological analysis
was performed on wound sections from mice at sacrifice
(Day 10), a time point at which the importance of these re-
pair processes are declining. Another contributing factor to
the lack of significant increase in wound macrophage con-
tent is that HDL has potent anti-inflammatory properties
and has been shown to reduce macrophage infiltration in
atherosclerotic plaques [32]. This anti-inflammatory effect
of HDL may therefore have counteracted any increases in
wound macrophage content as part of the repair process.
We also found no changes in wound collagen content be-
tween PBS and rHDL treated wounds. Collagen compos-
ition in old mice does not differ to that in young mice,
however, in mature wounds there is decreased collagen
deposition associated with age [15]. Our studies suggest
that rHDL has no effect on the ability of a wound to
deposit collagen.
VEGF is a key contributor to multiple components
of the wound healing cascade including angiogenesis,
epithelialization and collagen deposition [33]. Reduced
levels of VEGF are associated with delayed capillary
growth [15] and VEGF replacement can reverse impaired
angiogenesis in aged mice [34]. Hypoxia-inducible factor-
1α (HIF-1α) is induced in ischemic conditions to promote
angiogenesis and in turn promote the expression of potent
angiogenic factors such as VEGF. Furthermore, HIF-
1α is also post-translationally modulated. Upon hyp-
oxic stimulation, the E3 ubiquitin ligases Siah1 and
Siah2 are induced which suppress the expression of
prolyl hydroxylases (PHDs) PHD2 and PHD3. Under
normoxic conditions, the PHDs induce the ubiquitina-
tion and degradation of HIF-1α by hydroxylating spe-
cific prolyl residues. Studies from our laboratory have
shown that HDL augments ischemia driven angiogen-
esis in vivo and in vitro [8] and that these effects are
mediated via the post-translational stabilization of
HIF-1α [9]. Based on our previous findings with HDL
and as rHDL treatment increased the rate of wound
closure and wound angiogenesis in aged mice in the
current study, it may have been expected that there
would have been elevations in both VEGF and HIF-1α
in the tissues of the animals. We did not, however,
find any differences in these key angiogenic factors.
The lack of change may be due to the time point at
which the wounds were analyzed. VEGF is induced early
in the wound healing process to stimulate wound
angiogenesis and promote healing. Following this initial
a b
Fig. 6 The effect of rHDL infusions on hindlimb neovascularization. Femoral artery ligation was performed on 24-month-old C57B1/6 J mice. Mice
received i.v. injections of PBS or rHDL (40 mg/kg) on alternate days following ligation until sacrifice 21 days later. Upper panels are representative
images of stained hindlimb sections at the 21-day time point. White arrows highlight capillaries. a Capillaries were identified in non-ischemic
(NON) and ischemic (ISC) hindlimb sections using immunocytochemistry for CD31+ (red staining). (b) Arterioles were identified in non-ischemic
and ischemic hindlimb sections using immunocytochemistry for α-actin+ (green staining). Data is represented as mean ± SEM
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induction, VEGF levels then return to baseline. This is
consistent with the lack of change observed in these an-
giogenic markers in our study at the Day 10 time point. It
is also consistent with the increase VEGF in the aged
fibroblasts following incubation with rHDL in our in vitro
studies.
In addition to the deleterious impact that aging has on
wound healing, studies have also shown that angiogenesis
a b
c d
e f
g
Fig. 7 The effect of rHDL on angiogenic markers in ischemic hindlimbs. Femoral artery ligation was performed on 24-month-old C57B1/6 J mice.
Mice received i.v. injections of PBS or rHDL (40 mg/kg) on alternate days following ligation until sacrifice 21 days later. On Day 21 post-surgery
hindlimb tissue was collected and RNA isolated for qRT-PCR on non-ischemic (NON) and ischemic (ISC) hindlimbs to assess gene expression of
(a) Siah1; (b) Siah2; (c) PHD2; (d) PHD3; (e) HIF-1α; and (f) VEGF, normalized to β2-microglobulin (B2M). g VEGF protein was determined on
homogenized hindlimbs using ELISA. Data is represented as mean ± SEM. Statistical analysis was performed by one-way ANOVA and Bonferroni’s
comparison test post hoc. *p < 0.05 vs. PBS controls
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is responsible for collateral development (such as that
seen in peripheral limb ischemia) and is impaired with
aging, often leading to amputation [35]. Neovasculariza-
tion is a critical part of the recovery process after ischemia
[36] and aged patients show decreased capillary formation
in response to ischemia [37, 38]. We have recently shown
that HDL can augment ischemia-mediated angiogenesis in
young mice [8]. The current study has now found that
HDL can augment angiogenesis in the hindlimb ischemia
model in aged animals. In the aged mice we observed that
blood flow recovery was slower than in our previous work
in young mice. In young mice blood perfusion starts to
increase at 4–6 days post-femoral artery ligation and at
10–14 days blood perfusion levels are at ~80 % of the ori-
ginal blood flow before the ligation [8]. In the aged mice
infused with PBS, blood flow recovery does not go above
40 % for the entire experimental period of 21 days. Only
in mice infused with rHDL does blood flow increase to
50–70 % in the final experimental week. This suggests that
rHDL is able to overcome age-impaired neovasculariza-
tion in response to ischemia. In support of our observa-
tions of improved blood flow in rHDL infused aged mice,
we observed that in ischemic hindlimbs there was no loss
of toes in mice that had been infused with rHDL. The
ability of rHDL to prevent tissue necrosis and toe loss is
likely due to the promotion of blood flow perfusion in the
final week in these aged mice. There was also a >90 %
increase in hindlimb CD31+ neovessels which is consistent
with the increase in blood perfusion and protection
Fig. 8 rHDL increases VEGF in fibroblasts from aged mice.
Fibroblasts from aged mice were incubated with PBS (control) or
rHDL for 16 h. VEGF protein was assessed on harvested cell lysates
using western blotting. Cells from three donors were tested in
quintuplicate (n = 15). Data is represented as mean ± SEM. *p < 0.05
Fig. 9 rHDL infusions increase plasma total cholesterol and HDL cholesterol. Femoral artery ligation was performed on 24-month-old C57B1/6 J mice.
Mice received i.v. injections of PBS or rHDL (40 mg/kg) on alternate days following ligation until sacrifice 21 days later. Whole blood was collected via
cardiac puncture at the 21 day time point and plasma isolated. a Total cholesterol concentrations were determined enzymatically on mouse plasma
using commercially available kits; b HDL cholesterol concentrations were determined by enzymatic assay following precipitation of apolipoprotein B
containing proteins with polyethylene glycol; c LDL levels were determined by subtracting total HDL from total cholesterol. d Triglyceride levels were
determined enzymatically on mouse plasma using commercially available kits. Data is represented as mean ± SEM. Statistical analysis was performed
by unpaired two-tailed t-test. **p < 0.01 vs. PBS control
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against tissue necrosis in rHDL infused mice. We did not,
however, see any changes in arterioles. Very few arterioles
were detected in the hindlimb sections of these aged mice
and perhaps a reflection of the delay in neovascularization
and subsequent lack of maturation into arterioles by the
Day 21 time point.
We have previously found that rHDL augments VEGF
levels in ischemic hindlimbs in young mice [8]. This
study, however, found that mRNA levels of VEGF were
significantly lower in the hindlimbs of mice infused with
rHDL and there was no change in hindlimb VEGF pro-
tein. The end points in our previous studies was 10 or
14 days. It is possible therefore that our results for VEGF
expression in aged mice may indicate that rHDL-
induced increases in hindlimb VEGF occur earlier post-
ligation than at the 21 day time point at which they were
measured.
Conclusions
In conclusion, in aged mice rHDL increased wound clos-
ure and wound angiogenesis, and augmented blood per-
fusion in ischemic hindlimbs, preventing tissue necrosis.
These studies demonstrate the efficacy of rHDL for the
treatment of angiogenesis-related diseases that are asso-
ciated with aging and highlight an alternate therapeutic
pathway for the translation of HDL to clinic.
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